Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

557
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
557
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

1.1K
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
1.1K
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

604
CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its...
604
Drug Classes and Categories01:25

Drug Classes and Categories

2.6K
Drugs can be classified according to their chemical composition or their intended therapeutic application. For instance, anti-infective agents that possess the ability to eliminate pathogens or suppress their growth and reproduction can be grouped based on the organisms they target or their chemical structure. Furthermore, drugs can be divided into prescription, nonprescription, or controlled substances. Prescription medications, such as antibiotics, require oversight from a licensed healthcare...
2.6K
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

626
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
626
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

388
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
388

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patterns, motivations, and healthcare experiences of medical cannabis use among gender and sexuality diverse people in Australia: findings from the Cannabis as Medicine Survey 2022 (CAMS-22).

Harm reduction journal·2026
Same author

Cannabidiol reduces atypical absence seizures and epileptic spasms in a Gabrb3<sup>+/D120N</sup> mouse model of Lennox-Gastaut syndrome.

Epilepsia open·2026
Same author

High-dose cannabidiol for chronic neuropathic pain associated with spinal cord injury: a randomised clinical trial.

EClinicalMedicine·2026
Same author

Behavioural, pharmacokinetic, and genetic evidence of a cannabidiol-oxycodone drug-drug interaction in mice.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Urinary Δ<sup>9</sup>-tetrahydrocannabinol and metabolite concentrations following cannabis use: A systematic review.

Pharmacological research·2026
Same author

The effect of daily aerobic cycling exercise on cannabis withdrawal: An inpatient randomised controlled trial.

Scientific reports·2026

Related Experiment Videos

Prescribing medicinal cannabis.

Jonathon C Arnold1,2, Tamara Nation1,2, Iain S McGregor1,2

  • 1University of Sydney.

Australian Prescriber
|October 23, 2020
PubMed
Summary
This summary is machine-generated.

Medicinal cannabis access in Australia has expanded since 2016, with over 100 products available. Doctors remain cautious due to limited evidence and potential risks, particularly with delta-9-tetrahydrocannabinol.

Keywords:
cannabidiolmedical marijuanamedicinal cannabistetrahydrocannabinol

Related Experiment Videos

Area of Science:

  • Medical Research
  • Pharmacology
  • Public Health Policy

Background:

  • Australia legalized medicinal cannabis in 2016, leading to over 100 available prescription products, primarily oils and capsules containing delta-9-tetrahydrocannabinol (THC) or cannabidiol (CBD).
  • Prescribing unregistered cannabis products requires special government approval, typically via the Therapeutic Goods Administration's Special Access Scheme Category B or the Authorised Prescriber Scheme.

Purpose of the Study:

  • To review the landscape of medicinal cannabis prescribing in Australia.
  • To identify common indications, prescribing trends, and physician concerns regarding medicinal cannabis.
  • To assess the regulatory framework and patient access pathways.

Main Methods:

  • Analysis of Australian government data on medicinal cannabis approvals.
  • Review of prescribing guidelines and available product types.
  • Summary of reported indications and physician-reported concerns.

Main Results:

  • Over 28,000 prescribing approvals were issued by end of 2019, with projections exceeding 70,000 by end of 2020, involving over 1400 doctors.
  • Commonly prescribed for chronic non-cancer pain, anxiety, cancer symptoms, epilepsy, and neurological disorders, though evidence varies.
  • Physician caution persists due to concerns about driving impairment, cognitive effects, and dependence with THC-containing products, while CBD-only products are perceived as lower risk.

Conclusions:

  • Medicinal cannabis prescribing has significantly increased in Australia under specific regulatory schemes.
  • While access is expanding, limited evidence for some indications and safety concerns necessitate careful prescribing practices.
  • Further research is needed to solidify evidence for efficacy and safety across various conditions.